

## Amendments to the Claims

### Listing of Claims

The following Listing of Claims replaces all prior versions and listings of claims in the application.

1-21. (cancelled)

22. (currently amended) A composition comprising a plurality of solid amorphous dispersion particles comprising a substantially amorphous drug and a polymer selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, polyvinyl alcohols that have at least a portion of their repeat units in hydrolyzed form, polyvinyl pyrrolidone, poloxamers, and blends thereof wherein said particles have an average diameter of at least 40  $\mu\text{m}$  and a bulk specific volume of less than 5 mL/g, and wherein at least ~~80~~ 90 vol % of said particles have diameters of greater than 10  $\mu\text{m}$  and wherein said particles are formed by a spray drying process, said process comprising the steps

- (a) forming a feed solution comprising said drug, said polymer, and a solvent in which both said drug and said polymer are soluble;
- (b) directing said feed solution to a spray-drying apparatus;
- (c) atomizing said feed solution into droplets in said spray-drying apparatus; and
- (d) contacting said droplets with a drying gas to form said particles.

23. (cancelled)

24. (original) The composition of claim 22 wherein said particles have an average diameter of at least 50  $\mu\text{m}$ .

25. (original) The composition of claim 22 wherein said particles have a bulk specific volume of less than 4 mL/g.

26. (previously presented) The composition of claim 22 wherein said drug is selected from the group consisting of antihypertensives, antianxiety agents, anticlotting agents, anticonvulsants, blood glucose-lowering agents, decongestants, antihistamines, antitussives, antineoplastics, beta blockers: anti-inflammatories, antipsychotic agents, cognitive enhancers, anti-atherosclerotic agents, cholesterol-reducing agents, antiobesity agents, autoimmune disorder agents, anti-impotence agents, antibacterial and antifungal agents, hypnotic agents, anti-Parkinsonism agents, anti-Alzheimer's disease agents, antibiotics, anti-depressants, antiviral agents, glycogen phosphorylase inhibitors, and cholesteryl ester transfer protein inhibitors.

27-29 (cancelled)

30. (previously presented) The composition of claim 22 wherein said polymer is hydroxypropyl methyl cellulose acetate succinate.

31-38 (cancelled)

39. (previously presented) The composition of claim 22 wherein said droplets have an average diameter of at least 50  $\mu\text{m}$  and a  $D_{10}$  of at least 10  $\mu\text{m}$ .

40. (previously presented) The composition of claim 22 wherein said droplets have a  $D_{90}$  of less than 300  $\mu\text{m}$ .

41. (previously presented) The composition of claim 22 wherein said droplets have a  $D_{90}$  of less than 250  $\mu\text{m}$ .

42. (previously presented) The composition of claim 22 wherein said droplets have a Span of less than 3.

43. (previously presented) The composition of claim 22 wherein said droplets have a Span of less than 2.